Existing drug is shown to inhibit virus that causes COVID-19
- Details
- Category: Research
Scientists from the University of Chicago have found that the drug masitinib may be effective in treating COVID-19.
The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads.
Thinking impaired in 60% of COVID-19 survivors
- Details
- Category: Research
In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San Antonio reported July 29 at the Alzheimer’s Association International Conference.
Advantages of intranasal vaccination against SARS-CoV-2
- Details
- Category: Research
There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.
Antibiotics may help to treat melanoma
- Details
- Category: Research
Some antibiotics appear to be effective against a form of skin cancer known as melanoma. Researchers at KU Leuven, Belgium, examined the effect of these antibiotics on patient-derived tumours in mice. Their findings were published in the Journal of Experimental Medicine.
Take your best shot: Which SARS-CoV-2 vaccine should I get, if any?
- Details
- Category: Research
Vaccine hesitancy continues to be a hurdle in the development of widespread immunity within the U.S. population as the COVID-19 pandemic enters its second year.
Researchers at the University of Cincinnati College of Medicine have developed a computerized decision analytic model to compare projected outcomes of three vaccine strategies:
Study shows why second dose of COVID-19 vaccine shouldn't be skipped
- Details
- Category: Research
The second dose of a COVID-19 vaccine induces a powerful boost to a part of the immune system that provides broad antiviral protection, according to a study led by investigators at the Stanford University School of Medicine.
The finding strongly supports the view that the second shot should not be skipped.
Are silver nanoparticles a silver bullet against microbes?
- Details
- Category: Research
Antimicrobials are used to kill or slow the growth of bacteria, viruses and other microorganisms. They can be in the form of antibiotics, used to treat bodily infections, or as an additive or coating on commercial products used to keep germs at bay. These life-saving tools are essential to preventing and treating infections in humans, animals and plants, but they also pose a global threat to public health when microorganisms develop resistance to them, a concept known as antimicrobial resistance.
More Pharma News ...
- One shot of the Sputnik V vaccine triggers strong antibody responses
- "Long COVID": More than a quarter of COVID-19 patients still symptomatic after 6 months
- Artificial intelligence could be new blueprint for precision drug discovery
- Anti-tumor agent from the intestine
- mRNA vaccines slash risk of COVID-19 infection by 91% in fully vaccinated people
- Cancer cells eat themselves to survive
- Researchers find potential path to a broadly protective COVID-19 vaccine using T cells